Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Vicagrel
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Jiangsu Vcare Files NDA for Vicagrel Capsules with US FDA
Details : Vicagrel is an oral small molecule, P2Y12 receptor antagonist, which is under phase 2 clinical developmet for the treatment of coronary artery diseases.
Product Name : Vicagrel
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 01, 2024
Lead Product(s) : Vicagrel
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable